Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSA-KLH vs N-Propionylated PSA-KLH Vaccine in SCLC
NCT00004249Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 1998
- Primary completion
- Nov 2001
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PSA-KLH vaccine in small cell lung cancer (SCLC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Antibody response after immunization at 1 year. Started Aug 1998; status: completed.
02
Drugs
PSA-KLH vaccine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00004249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004249.